Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.36 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$207.33M
Enterprise Value$104.33M
Total Cash (Recent Filing)$56.31M
Total Debt (Recent Filing)$11.53M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 24, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding216,505,890
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.42
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data ReadoutsAnalyst notes that additional TN-401 data expected in the first half of 2026 could confirm early functional benefit and a tolerable safety profile, serving as a clear clinical proof-of-concept catalyst.
Financial RunwayA strengthened cash position and non-dilutive funding from collaborators support continued clinical execution and regulatory interactions, preserving optionality across multiple discovery targets.
Strategic PartnershipPartnership with an established RNAi company provides external validation, transfers late-stage development and commercialization responsibility, and reduces technical risk for Tenaya's target-to-therapy translation.
Bears Say
Clinical Consistency And Competitive PositioningSmall patient cohorts, mixed individual responses and comparatively smaller biomarker increases versus peer programs limit confidence in the program's competitive advantage and predictability of benefit.
Financial TransparencyDeclining to provide detailed financial breakdowns for individual targets creates uncertainty about the value of each discovery and complicates investor valuation of the pipeline.
Regulatory ClarityUncertainty about how clinical updates will translate into regulatory agreement on pivotal study designs raises the risk of delays and unclear approval pathways.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $207.33M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 13 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.028.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,505,890 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 11.719%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.00 (125.56% Upside)
$3.00 (125.56% Upside)
Hedge Fund Trend
Increased
By 178.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-95.46%
Trailing 12-Months
Asset Growth
-25.32%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$3.00
▲(125.56% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
54.87% Insiders
2.54% Mutual Funds
0.36% Other Institutional Investors
37.95% Public Companies and Individual Investors